Who is sponsoring NCT05805709?

NCT05805709 is sponsored by University of Pittsburgh.

What drugs are being tested in NCT05805709?

Interventions in NCT05805709: Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education.

What condition does NCT05805709 study?

NCT05805709 studies Acute Kidney Injury.

Is NCT05805709 still recruiting?

NCT05805709 is currently recruiting now. Last updated 4 September 2025.

Last reviewed 2025-09-04 · How we verify

NCT05805709: COPE-AKI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial

Recruiting now NA Last updated 4 September 2025

What this trial tests

NA trial testing Study Physician/Advance Practice Provider in Acute Kidney Injury in 2,145 participants. Currently enrolling.

Timeline

5 September 2023

Primary endpoint
5 June 2026

5 March 2027

Quick facts

Lead sponsor	University of Pittsburgh
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	2,145
Start date	5 September 2023
Primary completion	5 June 2026
Estimated completion	5 March 2027
Sites	9 locations across United States

Drugs / interventions tested

Study Physician/Advance Practice Provider
Nurse Navigator
Pharmacist
Patient Education — full drug profile →

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →

Sponsor

University of Pittsburgh

Who can join

18 and older, any sex, with Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rates of recurrent AKI, and changes in patient-reported outcomes. Participants (N=2145) will be allocated 1:1 to the intervention or usual care using a web-based system to maintain allocation concealment using stratified randomization with randomly permuted blocks. Randomization will be stratified by clinical site.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Unveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach.
Pan SY, Huang TT, Jiang ZH, Lin LC, et al · · 2024 · cited 5× · PMID 38934037 · DOI 10.23876/j.krcp.23.289
Improving Processes of Care after Acute Kidney Injury.
Gregg LP, Leaf DE, Leaf DE. · · 2025 · PMID 39446577 · DOI 10.1681/asn.0000000548

Verify or expand the search:

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Other University of Pittsburgh trials

Trials by the same sponsor.

NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05805709 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
Last refreshed: 4 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05805709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing